Imexpharm Corporation (HOSE:IMP)
Vietnam · Delayed Price · Currency is VND 54,000
-100 (-0.18%)
At close: Feb 9, 2026
Imexpharm Cash Flow Statement
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Jan '24 Jan 1, 2024 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 349,138 | 320,862 | 299,556 | 223,540 | 189,095 |
Depreciation & Amortization | 102,976 | 104,235 | 82,642 | 60,386 | 60,412 |
Other Amortization | 1,742 | 1,402 | - | - | - |
Loss (Gain) From Sale of Assets | -19,864 | -8,759 | -22,410 | -19,861 | -18,628 |
Other Operating Activities | -147,657 | -128,550 | -32,171 | -6,126 | -45,582 |
Change in Accounts Receivable | -21,484 | -83,307 | -30,534 | 20,136 | 115,759 |
Change in Inventory | 25,990 | -6,181 | -260,749 | 52,398 | -66,129 |
Change in Accounts Payable | 34,187 | 20,278 | 25,481 | 39,580 | -2,831 |
Change in Other Net Operating Assets | -270,857 | -3,711 | -101,351 | 7,018 | -2,159 |
Operating Cash Flow | 54,171 | 216,268 | -39,535 | 378,603 | 234,881 |
Operating Cash Flow Growth | -74.95% | - | - | 61.19% | 221.08% |
Capital Expenditures | -26,879 | -96,771 | -63,530 | -99,353 | -52,857 |
Sale of Property, Plant & Equipment | 1,127 | 4,832 | 2,533 | 582.73 | 8,655 |
Investment in Securities | -70,102 | -42,935 | 118,300 | -118,327 | -244,945 |
Other Investing Activities | 19,270 | 7,675 | 21,817 | 17,794 | 10,106 |
Investing Cash Flow | -76,584 | -127,199 | 79,121 | -199,304 | -83,142 |
Short-Term Debt Issued | - | 387,994 | 229,739 | 59,803 | - |
Long-Term Debt Issued | 666,889 | - | - | - | 324,785 |
Total Debt Issued | 666,889 | 387,994 | 229,739 | 59,803 | 324,785 |
Short-Term Debt Repaid | - | -351,294 | -275,298 | - | - |
Long-Term Debt Repaid | -540,232 | - | - | -231,514 | -190,282 |
Total Debt Repaid | -540,232 | -351,294 | -275,298 | -231,514 | -190,282 |
Net Debt Issued (Repaid) | 126,658 | 36,700 | -45,558 | -171,711 | 134,503 |
Common Dividends Paid | -77,004 | -70,005 | -66,672 | -100,007 | -100,007 |
Financing Cash Flow | 49,653 | -33,305 | -112,230 | -271,718 | 34,496 |
Foreign Exchange Rate Adjustments | -30.66 | 19.18 | -0.59 | -9.19 | -230.63 |
Net Cash Flow | 27,210 | 55,783 | -72,645 | -92,428 | 186,004 |
Free Cash Flow | 27,292 | 119,497 | -103,064 | 279,250 | 182,024 |
Free Cash Flow Growth | -77.16% | - | - | 53.41% | - |
Free Cash Flow Margin | 1.12% | 5.42% | -5.17% | 16.99% | 14.37% |
Free Cash Flow Per Share | 177.21 | 775.91 | -669.21 | 1813.19 | 1181.89 |
Cash Interest Paid | 16,382 | 3,491 | 6,700 | 4,475 | 4,227 |
Cash Income Tax Paid | 101,014 | 70,806 | 83,992 | 59,624 | 45,310 |
Levered Free Cash Flow | 380,110 | 145,454 | -69,934 | 274,201 | 211,391 |
Unlevered Free Cash Flow | 390,423 | 147,635 | -66,162 | 276,573 | 214,826 |
Change in Working Capital | -232,165 | -72,921 | -367,153 | 120,664 | 49,583 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.